Bionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies
January 11 2022 - 5:11PM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solutions for visualization, interpretation
and reporting of genomic data, hosted the second day of 2022
Symposium, the Company’s premiere event showcasing OGM research
applications across key clinical areas of constitutional genetic
disease, hematologic malignancies, solid tumors and OGM combined
with next-generation sequencing (NGS).
Ten presentations from leading researchers across North
America and Europe showcased the utility of OGM for hematologic
malignancies at 2022 Symposium. Ten experts from across
North America and Europe shared their latest research using OGM to
characterize genetic aberrations in a wide variety of adult and
pediatric leukemias and related hematologic malignancies. Their
findings consistently demonstrated the sensitivity of OGM for
structural variants typically identified by karyotyping and FISH.
These researchers also shared examples of novel variants of
potential clinical importance discovered with OGM that were
undetected with other methods.
OGM revealed novel genetic aberrations in B-cell Chronic
Lymphocytic Leukemia (B-CLL) and Acute Lymphoblastic Leukemias
(ALL). B-CLL is the most common form of adult leukemia.
Karyotyping and FISH panels for characterized genetic aberrations
are typically used in the evaluation of B-CLL. Dr. Saurabh Gupta,
from Quest Diagnostics, has focused his initial evaluation of OGM
on this malignancy and shared the overall high concordance of OGM
with traditional methods to detect known gene rearrangements in
B-CLL. He also described cases in which OGM identified variants
that were missed or not fully characterized by conventional methods
but were of potential prognostic value. Dr. Anna Puiggros from
Hospital del Mar in Barcelona, Spain presented her similar findings
that OGM effectively detected genetic aberrations and several
additional abnormalities in chronic lymphocytic leukemia (CLL)
samples in an independent study.
OGM can be faster and more cost-effective than
traditional techniques for analyzing ALL. ALLs are
hematopoietic neoplasms of lymphoid precursors, characterized by
the accumulation of malignant, immature lymphoid cells in the bone
marrow and blood. The classic panel for these types of neoplasms
includes karyotyping, FISH, and multiplex ligation-dependent probe
amplification (MLPA). In two independent studies, Jonathan L.
Lühmann, from Hannover Medical School, Germany, and Dr. Barbara
Dewaele, from University Hospitals, Leuven, found that OGM reliably
and cost-effectively identified genetic markers when compared to
traditional panels for ALL. In addition to accurately identifying
all translocations, the studies found that OGM detected additional
potentially targetable new fusions and chromothripsis. Further, Dr.
Adrian Dubuc presented a case study of a 37-year-old veteran who
was diagnosed as Philadelphia-negative B-ALL. Based on a battery of
cytogenetics tests, this patient was found to have a complex
genetic profile. Using OGM alone, Dr. Dubuc and his team were able
to confirm this same complex profile.
OGM detected more clinically relevant variants across a
wide range of hematologic malignancies including acute myeloid
leukemia (AML). Other presenters shared study results
evaluating the OGM workflow for a variety of different hematologic
malignancies. Dr. Kornelia Neveling is investigating whether OGM
could replace traditional tests such as karyotyping and FISH and is
conducting a clinical utility study for subjects with AML. She
reported that interim analyses for this study support this
potential application. Data from similar comparative analyses were
presented by Bence Dvorak on plasma cell diseases, Dr. Elena Garcia
Sanchez on pediatric leukemias, Dr. Brynn Levy for AML, and Dr.
Adam Smith on multiple malignancy types. These independent studies
suggest that OGM can detect known and novel genetic aberrations,
facilitate interpretation and reporting, and reduce time from
procuring the sample to reporting data.
“We continue to be impressed by the work of our colleagues and
are grateful for their contributions to genetic discovery in
cancer,” remarked Alka Chaubey, PhD, FACMG, Chief Medical Officer
of Bionano. “We are excited by the potential of OGM to identify new
variants that may directly impact the lives of people living with
leukemia and related conditions.”
“As these presenters demonstrated today, we are just beginning
to see how OGM can better characterize genetic variants in
hematologic malignancies,” commented Erik Holmlin, PhD,
President and Chief Executive Officer of Bionano. “These
presentations demonstrate that OGM is a scalable workflow that can
reliably match traditional methods, which we believe may unlock new
insights into cancer.”
Don’t miss Symposium, register now! Symposium
registration is open to all and there is no charge for attending
this event. Register today at
https://www.labroots.com/ms/virtual-event/bngo2022.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome
through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which integrates
next-generation sequencing and microarray data designed to provide
analysis, visualization, interpretation and reporting of copy
number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability and
utility of OGM to analyze genomes and reliably identify and
characterize genetic variants, the ability for OGM to unlock
insight into cancers or to affect the lives of people with cancer,
and the potential for OGM to become part of the standard of care.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape, including the
introduction of competitive technologies or improvements in
existing technologies; failure of future study results to support
those demonstrated during the presentations referenced in this
press release; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans
and commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of OGM or our technologies; and the risks and uncertainties
associated with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2020 and in other filings subsequently made by us
with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024